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e.2013.03Abstract Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer mortality
among men worldwide. Serotonin is a biogenic amine, ligand of a family of 5-HT receptors that
reﬂect the diversity of serotonergic actions. Majority of serotonin in body (90%) is synthesized
by enterochromafﬁn cells of the gastrointestinal tract and is exported to various sites. Serotonin reg-
ulates blood ﬂow and vascular tone at portal and sinusoidal levels, serotonin acts as a mitogen for
hepatocytes and promotes liver regeneration. 5HT emerges as a mediator of different pathological
conditions (double edged sword). It contributes to liver ﬁbrosis, mediates oxidative stress in nonal-
coholic steatotic hepatitis and aggravates viral hepatitis, these conditions are involved in tumouri-
genesis of hepatocellular carcinoma (HCC). Impaired metabolic function in liver cirrhosis and slow
uptake and storage of serotonin by the platelets is a sequelae of kinetic change of serotonin trans-
port mechanisms or abnormal serotonin release from dense granules of activated platelets is a con-
dition deﬁned as ‘‘platelet exhaustion’’, contributes to elevated plasma serotonin which may
facilitate tumour growth of primary liver hepatocellular carcinoma.
Aim of this work: To determine whether serotonin is a marker for the diagnosis of hepatocellular
carcinoma in cirrhotic patients.
Methods: Patients were classiﬁed into two groups; 45 patients with cirrhosis only and 30 patients
with cirrhosis and HCC. Ten healthy subjects were taken as controls. Patients underwent; full his-
tory taking, clinical examination, and abdominal ultrasonography. Laboratory methods include
SGOT, SGPT, GGT, bilirubin, alkaline phosphatase, total proteins, albumin, CBC, prothrombin,
INR, APRI score, Child-pugh score, MELD score, AFP and serum serotonin.
Results: Plasma serotonin was signiﬁcantly higher in the patients group with cirrhosis with a median
level of 119.4 ng/ml than in the control group which showed a median value of 51.5 ng/ml p< 0.001.oo.com (H.A. Abd El Moety).
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370 H.A. Abd El Moety et al.A signiﬁcance difference was also seen between cirrhosis and the HCC group with a median value of
478.35 ng/ml than the control group and a cirrhosis group with p< 0.001was found.
Conclusion: Plasma serotonin level was signiﬁcantly higher in patients with cirrhosis and HCC than
in those with cirrhosis only and it was involved in the tumourigenesis of hepatocellular carcinoma.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Alexandria University Faculty of Medicine.1. Introduction
Each year, hepatocellular carcinoma (HCC) is diagnosed in
more than half a million people worldwide, including approx-
imately 20,000 new cases in the United States.1 Liver cancer is
the ﬁfth most common cancer in men and the seventh in
women. Most of the burden of disease (85%) is borne in devel-
oping countries.2 Incidence of HCC in Egypt is currently
increasing, which may be the result of a shift in the relative
importance of HBV and HCV as primary risk factors in addi-
tion to exposure to aﬂatoxin as an additional risk factor.3–5
HCC is the second most frequent cause of cancer incidence
and mortality among men in Egypt.6 Egypt has the highest
prevalence of HCV in the world, with estimates ranging from
6% to 28% and a reported average of 13.8%, also investiga-
tions in Egypt have also shown the increasing importance of
HCV infection in the aetiology of HCC, accounting for
40–50% of cases.3,5,7,8
HCV mostly plays an indirect role in tumour development
and appears to increase the risk of HCC by promoting ﬁbrosis
and cirrhosis.5,9 On the other hand, HCV may play a direct
role in hepatic carcinogenesis through the involvement of viral
gene products in inducing liver cell proliferation. However, it
seems that cirrhosis is the common pathway by which several
risk factors exert their carcinogenic effects.9,10
The diagnosis of HCC is made by liver imaging tests such as
abdominal ultrasound, helical CT scan or triple phase CT scan
in combination with the measurement of serum markers such
as alpha-fetoprotein (AFP) which has been used as a serum
marker for HCC for many years but this test had a sensitivity
of 39–65%, a speciﬁcity of 76–94% in the presence of
HCC.11,12
Unfortunately, up to 42% of patients with HCC present
with serum AFP levels within normal values and also the
ﬁbrolamellar type of HCC do not secrete AFP.13,14 On the
other hand, the AFP could also be elevated in pregnancy,
other tumours of gonadal origin even in acute or chronic viral
hepatitis and liver cirrhosis.11,15,16
Serotonin is known as 5-hydroxytryptamine (5-HT), a bio-
genic amine that functions as a ligand for a large family of 5-
HT receptors.17 The majority of serotonin in the body (90%) is
synthesised by enterochromafﬁn cells of the gastrointestinal
(GI) tract, where it regulates intestinal motility.18
It plays a major role in neurotransmission within the cen-
tral nervous system (CNS) and the autonomic nervous system
(ANS). In the CNS serotonin is known to control mood,
behaviour, learning, sleep and anxiety. Peripherally, serotonin
is able to mediate vascular contraction and relaxation, cell pro-
liferation, apoptosis and platelet aggregation.19
Serotonin is actively taken up by cells expressing the Na+/
Cl dependent serotonin transporter (SERT) where it is
stored in intracellular vesicles and released in response tovarious stimuli. Once bound to target receptors or taken up
by the SERT, internalised serotonin can be metabolised by
monoamine oxidase (MAO) leading to the generation of
5-hydroxyindoleacetaldehyde (5-HIAA) which is excreted in
urine.19,20
Platelets are responsible for picking up serotonin from the
gut and lungs and provide the main peripheral storehouse of
serotonin, platelets release serotonin in sites of injury where
it contributes to platelet recruitment and thrombus
propagation.21,22
The family of receptors that bind serotonin is subdivided
into seven subgroups and where appropriate these subgroups
are again divided reﬂecting the diversity of serotonergic ac-
tions. All members of the serotonin receptor family are linked
to G-proteins, except the 5-HT3 receptor which is a ligand
gated Na+/K+ channel.19,23
With respect to the liver, it was found that serotonin has the
ability to regulate hepatic blood ﬂow at both the portal and
sinusoidal levels.19
Intraportal injections of serotonin were found to signiﬁ-
cantly increase portal pressure, events that were antagonised
by the serotonin antagonist (ketanserin) in portal hypertensive
rats, this suggests that serotonergic mechanisms may contrib-
ute to maintaining portal hypertension in patients with cirrho-
sis. Serotonin may play a role in hepatic regeneration following
partial hepatectomy in rodents.24–27 One resident of the hepa-
tic sinusoid that is postulated to regulate blood ﬂow is the he-
patic stellate cell (HSC). The HSC is known to undergo an
activation process acquiring a smooth muscle cell-like pheno-
type with enhanced contractile capabilities in response to liver
injury and are instructed by serotonin to make more scar tis-
sues and switch off the healthy regeneration, has also recently
been demonstrated to express functional 5-HT2A and 5-HT2B
receptors and therefore it is possible that HSC is able to regu-
late sinusoidal blood ﬂow. Sinusoidal endothelial cells (SECs)
are also known to respond to serotonin inducing contraction
of the fenestrae.28–30
Patients with advanced liver disease often present with
variceal haemorrhage and a more generalised ‘‘bleeding
tendency’’. These additional symptoms linked to hepatic
cirrhosis are thought in part to be due to impaired platelet
aggregation. Under normal conditions platelets operating as
buffers, maintain low levels of free circulating serotonin, are
activated in response to a variety of different stimuli, releasing
various aggregating factors including serotonin, and following
this they become exhausted.
Patients with cirrhosis are known to have platelet storage
pool defects, signiﬁcantly lower intraplatelet serotonin concen-
trations when compared to healthy individuals. It is therefore
tempting to propose that the reduced platelet serotonin storage
ability was in part responsible for the haemorrhagic tendency
of cirrhotic patients.19,31,32
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interconnection. The liver plays a critical role even during
the synthesis of platelets from megakaryocytes through throm-
bopoetin(TPO) which was the most important growth factor in
the regulation of megakaryocyte development and platelet pro-
duction, is produced mainly in the liver and kidney.
Hence platelets are not expected to function properly in dis-
eased liver. platelets harbour important growth factors for li-
ver regeneration, e.g. Hepatocyte growth factor (HGF).
Contrariwise, platelets contain Transforming growth factor a
(TGF-a), which is required for the termination of liver regen-
eration. Thus, it is plausible that platelets may participate in
orchestrating liver regeneration through the stimulation and
inhibition of growth-related signals. The ability of serotonin
to modulate all these factors renders it crucial in times of hepa-
tic injury and repair.33
Platelet derived serotonin has been shown to be beneﬁcial
in terms of stimulating hepatocyte proliferation following
hepatic ischaemia in mice.34 In addition over proliferation
of hepatocytes can lead to HCC and this would raise the
possibility that serotonin may play a role in HCC
pathogenesis.19
Serotonin is emerging as a mediator of different patholog-
ical conditions. It contributes to liver ﬁbrosis, mediates oxida-
tive stress in nonalcoholic steatotic hepatitis, and aggravates
viral hepatitis promoting the progression of steatohepatitis
by oxidative stress.30,35,36 It promotes tumour growth in a
mouse model of subcutaneous colon cancer allografts. 5HT
deﬁciency led to decreased vascularity and increased necrosis
reﬂecting cell death of the tumour.37
High levels of plasma serotonin in the liver cirrhosis could
be due to slow uptake and storage of serotonin by the platelets
as could be the sequelae of the kinetic change of serotonin
transport mechanisms or abnormal serotonin release from
dense granules of activated platelets. Concentration of circu-
lating serotonin in liver cirrhosis can be inﬂuenced by other
factors, such as altered serotonin catabolism due to an elevated
activity of monoamino oxidase and impaired metabolism of
tryptophan, as a serotonin precursor. Impaired metabolic
function in liver cirrhosis contributes to elevated plasma
serotonin.382. Aim
The aim of this work was to evaluate the role of serotonin in
the diagnosis of hepatocellular carcinoma in cirrhotic patients.3. Methods
The studied subjects were recruited from the hepatology
department in medical research institute, Alexandria university
Written conﬁned consent was obtained from all participants
before starting the study.
The patients were subdivided into two groups:
1- Forty-ﬁve cirrhotic patients (Group I).
2- Thirty cirrhotic patients with hepatocellular carcinoma
(HCC) (Group II).
3- Ten healthy persons were considered as the control
group.All subjects were subjected to full history taking, clinical
examination with measurement of mean blood pressure and
calculation of body mass index (BMI) using the formula:
weight in kg/height in meter2,39 in addition to an abdominal
ultrasonography and computed tomography.
Patients are matched for age, gender and body mass index.
All had clinically evident portal hypertension, none of them
had episodes of bacterial peritonitis and were free from other
neoplastic diseases.
A routine biochemical evaluation was performed as
follows:
(a) Liver function tests including serum aspartate and ala-
nine aminotransferase. (AST + ALT), gamma glutamyl
transpeptidase (GGT), alkaline phosphatase (ALP),
total proteins, albumin, bilirubin (Total and direct).40
(b) Complete blood picture, prothrombin activity and
INR.41
(c) Calculation of aspartate aminotransferase-to-platelet
ratio index (APRI) score using the formula: (AST/upper
limit of normal · 100)/platelet count. The reference
value of AST was considered to be 45 IU, which is the
upper normal limit in our laboratory.42
(d) Hepatitis virus markers: Hepatitis B surface antigen
done by the Eliza technique.43 Hepatitis C virus antibod-
ies done by the Eliza technique.44
(e) Child-Pugh45 and model of end stage liver disease
(MELD) scores were evaluated.46
(f) Determination of serum AFP47 and serotonin48 by the
Eliza technique.
3.1. Statistical analysis
Data were fed to the computer using the predictive Analytics
Software (PASW Statistics 18).
Qualitative data were described using number and percent.
Association between categorical variables was tested using
Chi-square test. When more than 20% of the cells have an ex-
pected count less than 5, correction for Chi-square was con-
ducted using the Firsher’s exact test or the Monte Carlo
correction.
Quantitative data were described using median, minimum
and maximum as well as mean and standard deviation.
The distributions of quantitative variables were tested for
normality using the Kolmogorov–Smirnov test and the Shap-
iro–Wilk test. D’Agstino test was used if there was a conﬂict
between the two previous tests. If it reveals normal data distri-
bution, parametric tests were applied. If the data were abnor-
mally distributed, non-parametric tests were used.
For normally distributed data, comparison between two
independent populations were done using the independent t-
test while when more than two populations were analysed
the F-test (ANOVA) was to be used and the post Hoc test
(LSD). Correlations between two quantitative variables were
assessed using the pearson’s coefﬁcient.
For abnormally distributed data, Mann–Whitney Test (for
data distribution that was signiﬁcantly deviated from normal)
were used to analyse two independent population. If more
than two population were analysed Kruskal Wallis test to be
used. Correlations between two quantitative variables were as-
sessed using Spearman coefﬁcient.
Table 2 Laboratory investigations in both patient groups.
Group I (n= 45) Group II (n= 30) Test of sig.
Creatinine (mg/dl)
Min–Max 0.50–2.80 0.60–2.20 p= 0.229
Mean ± SD 1.04 ± 0.42 1.10 ± 0.36
Median 0.90 1.10
372 H.A. Abd El Moety et al.Agreement of the different predictives with the outcome
was used and was expressed in sensitivity, speciﬁcity, positive
predictive value, negative predictive value and accuracy. Recei-
ver operating characteristic curve (ROC) was plotted to ana-
lyse a recommended cutoff, the area under the ROC curve
denotes the diagnostic performance of the test. Area of more
than 50% gives an acceptable performance and an area of
about 100% is the best performance for the test.
Signiﬁcance test results were quoted as two-tailed probabil-
ities. Signiﬁcance of the obtained results was judged at the 5%
level.
4. Results
Patients enrolled in this study were subdivided into two
groups:
Group I included 33(73.3%) cirrhotic males and 12 (26.7%)
cirrhotic females their mean age was 53.98 ± 9.07 years.
Group II included 17(56.7%) males and 13(43.3%) females
with liver cirrhosis and HCC, their mean age was
55.60 ± 93.95 years.Table 1 Clinical data of patient groups.
Group I (n= 45) Group II (n= 30) Test of sig.
Sex
Male 33(73.3%) 17(56.7%) p= 0.134
Female 12(26.7%) 13(43.3%)
Age(years)
Min–Max 38.0–75.0 34.0–74.0 p= 0.466
Mean ± SD 53.98 ± 9.07 55.60 ± 93.95
Median 52.0 54.0
BMI(kg/m2)
Min–Max 16.40–37.70 17.10–41.60 p= 0.200
Mean ± SD 26.56 ± 3.75 27.90 ± 5.17
Median 26.50 27.65
MBp(mmHg)
Min–Max 70.0–120.0 70.0–120.0 p= 0.663
Mean ± SD 87.57 ± 10.87 89.70 ± 12.79
Median 83.30 83.30
Child class
A 8 (17.8%) 1 (3.3%) p= 0.011*
B 27 (60.0%) 13 (43.3%)
C 10 (22.2%) 16 (53.3%)
Child class score
Min–Max 5.0–13.0 6.0–14.0 p= 0.015*
Mean ± SD 8.58 ± 1.90 9.63 ± 1.83
Median 9.0 10.0
MELD score
Min–Max 7.0–27.0 7.0–25.0 p= 0.235
Mean ± SD 13.60 ± 4.91 14.47 ± 4.19
Median 13.0 14.50
Group I = patients with liver cirrhosis.
Group II = patients with liver cirrhosis and hepatocellular
carcinoma.
BMI = body mass index.
MBp= mean blood pressure.
MELD=model of end stage liver disease.The healthy control group included 6(60%) males and
4(40%) females with matched age, gender and body mass in-
dex (BMI), their mean age was 48.40 ± 9.17 years.
Group I, 25 patients (55.6%) were bleeders; 32 patients
(71.1%) had ascites, 16 patients (35.6%) presented with
hepatic encephalopathy.
Group II, 13 patients (43.3%) were bleeders; 25 (83.3%)
had ascites and 10 patients (33.3%) presented with hepatic
encephalopathy with no signiﬁcant difference between both
groups.
Five patients (11.1%) of group I were hypertensive while 7
patients (23.3%) of group II were hypertensive and 4 patientsAST
Min–Max 10.0–186.0 23.0–309.0 p= 0.001*
Mean ± SD 53.40 ± 42.56 88.93 ± 64.90
Median 34.0 78.50
ALT
Min–Max 7.0–97.0 6.0–140.0 p= 0.001*
Mean ± SD 27.36 ± 20.21 44.37 ± 30.88
Median 20.0 33.50
Total Bilirubin
Min–Max 0.40–14.0 0.50–25.0 p= 0.058
Mean ± SD 2.56 ± 3.04 4.22 ± 5.16
Median 1.60 2.0
Direct Bilirubin
Min–Max 0.10–10.50 0.30–16.30 p= 0.026*
Mean ± SD 1.40 ± 2.15 2.63 ± 3.54
Median 0.70 1.05
Total proteins
Min–Max 4.40–8.60 5.40–8.80 p= 0.021*
Mean ± SD 6.73 ± 0.88 7.24 ± 0.96
Median 6.90 7.15
Albumin
Min–Max 1.60–4.50 1.50–3.50 p= 0.392
Mean ± SD 2.61 ± 0.64 2.42 ± 0.42
Median 2.50 2.45
GGT
Min–Max 6.30–208.0 14.0–479.0 p= 0.043*
Mean ± SD 43.69 ± 37.44 76.77 ± 90.83
Median 33.0 37.0
ALP
Min–Max 47.0–522.0 52.0–333.0 p= 0.041*
Mean ± SD 110.91 ± 81.84 145.30 ± 82.21
Median 87.0 128.0
Group I = patients with liver cirrhosis.
Group II = patients with liver cirrhosis and hepatocellular
carcinoma.
ALT = alanine aminotransferase.
AST = aspartate aminotransferase.
GGT= gamma glutamyl transpeptidase.
ALP = alkaline phosphatase.
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II had IHD.
In group I, 8 patients (17.8%) were of child class A, 27 pa-
tients (60.0%) were of child class B and 10 patients (22.2%)
where of child class C. While in group II, 1patient (3.3%)
was of child class A, 13 patients (43.3%) were of child class
B and 16 patients (53.3%) were of child class C with signiﬁcant
difference between both groups (p= 0.011*) (Table 1).Table 3 Haematological investigations in both patient
groups.
Group I (n= 45) Group II (n= 30) Test of sig.
HB (g/dl)
Min–Max 5.80–13.20 6.90–14.50 p= 0.685
Mean ± SD 10.07 ± 1.79 9.89 ± 1.91
Median 9.80 9.55
WBCs · 103
Min–Max 1.16–15.80 1.90–13.27 p = 0.516
Mean ± SD 5.51 ± 2.92 5.29 ± 2.90
Median 4.76 4.11
Platelets · 103
Min–Max 35.0–255.0 35.0–209.0 p= 0.036*
Mean ± SD 130.80 ± 60.1 100.07 ± 47.08
Median 131.0 92.0
APRI score
Min–Max 0.17–2.83 0.32–5.29 p< 0.001*
Mean ± SD 1.08 ± 0.77 2.29 ± 1.48
Median 0.82 2.07
Proth activity
Min–Max 26.10–92.30 23.30–91.30 p = 0.665
Mean ± SD 52.17 ± 15.05 53.51 ± 16.30
Median 49.10 50.60
INR
Min–Max 1.04–2.50 1.06–3.20 p= 0.664
Mean ± SD 1.62 ± 0.38 1.62 ± 0.46
Median 1.60 1.54
Group I = patients with liver cirrhosis.
Group II = patients with liver cirrhosis and hepatocellular
carcinoma.
Hb = haemoglobin level.
NR= international normalised ratio.
APRI = aspartate aminotransferase-to-platelet ratio index.
* Statistically signiﬁcant at p 6 0.05.
Table 4 AFP and serotonin concentration in control and patient g
Control (n= 10) Group I (n
AFP (ng/ml)
Min–Max 2.0–10.0 1.58–63.90
Mean ± SD 5.73 ± 3.03 15.89 ± 17.
Median 5.10 10.30
Serotonin(ng/ml)
Min–Max 42.50–75.0 44.90–337.4
Mean ± SD 55.60 ± 12.36 148.22 ± 75
Median 51.50 119.40
Group I = patients with liver cirrhosis.
Group II = patients with liver cirrhosis and hepatocellular carcinoma.
AFP = a fetoprotein.The mean value of child class score in group I was
8.58 ± 1.90 while in group II, it was 9.63 ± 1.83 with signiﬁ-
cant difference between the two groups (p= 0.015*) (Table 1).
The mean value of MELD score in group I was
13.60 ± 4.91while in group II it was 14.47 ± 4.19 with no sig-
niﬁcant difference between both groups (p= 0.235) (Table 1).
AST, ALT, direct bilirubin and total proteins levels were
signiﬁcantly higher in group II than group I (p= 0.001*,
0.001*, 0.026* and 0.021*, respectively), while serum albumin
level showed no signiﬁcant difference between the two groups.
Also GGT and ALP were signiﬁcantly higher in group II than
group I (p= 0.043* and 0.041*, respectively) (Table 2).
No signiﬁcant difference between both groups as regards
HB level, WBC count, prothrombin activity and INR was
found (Table 3).
Platelats were signiﬁcantly lower in group II than group I
(p= 0.036*).
APRI score was signiﬁcantly higher in group II than group
I with a p value <0.001* (Table 3).
AFP serum concentration was signiﬁcantly higher in group
II showing a median value of [462.0(22.7–10271)] ng/ml than
in group I which showed median value of [10.30 (1.58–
63.90)] ng/ml with p3 < 0.001* (Table 4).
Also the serum concentration of AFP in both groups was
signiﬁcantly higher than the control group which showed a
median value of [5.10 (2–10)] ng/ml with [p1 < 0.001* and
p2 < 0.001*] (Table 4).
The serum concentration of serotonin in group II was
[478.35 (266.60–1577.40)] ng/ml which was signiﬁcantly higher
than in group I which showed a median value of [119.40
(44.90–337.40] ng/ml with p3 < 0.001*, also serotonin serum
concentration in both groups was signiﬁcantly higher than
the control group which slowed a median value of [51.50
(42.50–75) ng/ml], [p1 < 0.001* and p2 < 0.001*] (Table 4).
Serotonin serum concentration was signiﬁcantly higher in
child class C than child class B and A (p= 0.023*) (Table 5).
There was a signiﬁcant positive correlation between serum
serotonin concentration and AFP in group I and group II
(r= 0.298, p= 0.047*, r= 0.468, 0.009*, respectively)
(Table 6).
Serotonin showed negative signiﬁcant correlation with
APRI score in group II (r= 0.363, p= 0.049*), while in
group I the negative correlation between serotonin and APRI
score was not signiﬁcant (r= 0.064, p= 0.675) (Table 7).roups.
= 45) Group II (n= 30) p value
22.70–10271.0 p1 = 0.022*
30 1406.96 ± 2213.02 p2 < 0.001*
462.0 p3 < 0.001*
0 266.60–1577.40 p1 < 0.001*
.77 652.86 ± 343.56 p2 < 0.001*
478.35 p< 0.001*
Table 5 Relation between child class and serotonin in total patients.
Child class p
A (n= 9) B (n= 40) C (n= 26)
Serotonin
Median (Min–Max) 172.10(81.10–311.10) 196.05(44.90–1317.70) 365.25(49.10–1577.40) 0.023*
Mean ± SD 167.53 ± 71.99 297.09 ± 283.39 463.63 ± 393.42
p: p value for Kruskal Wallis test.
* Statistically signiﬁcant at p 6 0.05.
Table 6 Correlation between AFP and serotonin.
Serotonin
Control Group I Group II
AFP rs 0.442 0.298
* 0.468*
p 0.200 0.047 0.009
Group I = patients with liver cirrhosis.
Group II = patients with liver cirrhosis and hepatocellular
carcinoma.
AFP = a fetoprotein.
rs: Spearman coefﬁcient.
* Statistically signiﬁcant at p 6 0.05.
Table 7 Correlation between serotonin and APRI.
Serotonin
Group I Group II
APRI rs 0.064 0.363*
p 0.675 0.049
Group I = patients with liver cirrhosis.
Group II = patients with liver cirrhosis and hepatocellular
carcinoma.
APRI = aspartate aminotransferase-to-platelet ratio index.
Figure 1 ROC curve for AFP and serotonin in liver Cirrhosis
group.
Figure 2 ROC curve for AFP and serotonin in liver Cirrhosis
and HCC group.
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4.1.1. A; Group I: (Fig. 1)
*AFP area under ROC curve (AUROC) at cut off (10 ng/ml)
was 0.733
p= 0.074 showing 51.11% sensitivity 100% ppV, 100%
speciﬁcity, 31.25% NpV and 60% accuracy.
*Serotonin AUROC with a cut off value of 75 ng/ml (0.939
p= 0.031) showed 86.67% sensitivity and 100% speciﬁcity
with 62.50% NPV and 89.09% accuracy.
4.1.2. B; Group II: (Fig. 2)
AFP at cut off of 10 ng/ml in the area under ROC curve was
0.980 p= 0.018 showing 93.33% sensitivity with 100% PPV
and 100% speciﬁcity with 83.3% NPV and 95% accuracy .
Serotonin with cut off of 75 ng/ml was 1.000 p< 0.001
showing 100% diagnostic performance.
5. Discussion
Hepatocellular carcinoma is the ﬁfth leading cause of cancer
and the third leading cause of cancer death.49 This cancer var-
ies widely in incidence throughout the world, with rising
Serotonin: Is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? 375incidence in Egypt.5,8 In general, almost all HCC cases are pre-
ceeded by chronic hepatitis or liver cirrhosis which is mainly
caused by hepatitis B and hepatitis C.50 Despite the
surveillance programs for high-risk patients, it is still a medical
issue that many patients have an unresectable HCC at the time
of diagnosis.51
Ultrasound (US) screening is superior to AFP assay for the
detection of HCC but combined use of AFP monitoring and
US is recommended in patients with chronic HCV.52,53
Serotonin (5HT), a well-known neurotransmitter within the
central nervous system, also regulates a wide range of physio-
logical actions in the gastrointestinal tract.54 5HT is a potent
mitogen for many different cell types, including hepatocytes.55
Within the liver, 5HT has the ability to regulate hepatic blood
ﬂow at both the portal and sinusoidal levels and it may play a
role in hepatic regeneration.19 Serotonin has been shown to
mediate the pathology of many liver diseases, such as steato-
hepatitis, chronic cholestasis, viral hepatitis and liver cirrho-
sis.30,35 All these conditions are involved in the
tumourigenesis of HCC.56
After the application of serotonin inhibitors, portal pres-
sure is decreased in patients with liver cirrhosis, conﬁrming
the importance of serotonin in the pathogenesis of portal
hypertension.57 On the other hand, higher serotonin levels
are associated with improved antiviral treatment outcomes in
patients with HCV.58 These ﬁndings make serotonin both a
friend and foe of the liver.59
AFP seems to be of prognostic value at the time of tumour
diagnosis. A high concentration in HCC is associated with
greater tumour size, bilobar involvement, portal vein invasion,
and a lower median survival rate.60
Farinati et al.61concluded that AFP was not a sensitive
marker to detect the presence of HCC. Also, the prognostic va-
lue of AFP is limited, but it is correlated with the overall sur-
vival in untreated patients.
Recent data suggest that the use of AFP as a diagnostic test
is less speciﬁc than was once thought. Since it can be elevated
in liver cirrhosis and other malignancies, it is recommended
that it is no longer be used for the diagnosis of HCC.62 In
our work, serum AFp was signiﬁcantly higher in patients than
healthy subjects (p1 = 0.022* and p2 < 0.001*) also it was sig-
niﬁcantly higher in group II than group I (p3 < 0.001*),
although it was higher than normal in some patients with liver
cirrhosis without HCC (Table 4).
Baig et al.63 concluded that AFP was a signiﬁcant marker
for HCC and also an indicator of HCC risks mostly in patients
with cirrhosis and HCV/HBV infections. In a study conducted
in Chinese patients with chronic hepatitis B, 44 patients were
found to have an elevated AFP. Of these, only six had HCC.64
In our work, plasma serotonin level was signiﬁcantly higher
in patients than healthy subjects (p1 < 0.001* and
p2 < 0.001*) also it was signiﬁcantly higher in group II than
group I (p3 < 0.000*) (Table 4).Table 8 Agreement (sensitivity, speciﬁcity and accuracy) for AFP a
Control Liver Cirrhosis Se
AFp >10 10 22 51
610 0 23
Serotonin >75 10 6 86
675 0 39Serum serotonin concentration was signiﬁcantly higher
in child class C than child class A and B (p= 0.023*)
(Table 5).
Culaﬁc et al.38 found a statistically signiﬁcant difference be-
tween serotonin plasma values in patients with liver cirrhosis
and healthy subjects, moreover they found that its level was
signiﬁcantly higher in Child-pugh grade A/B than in grade C
patients but platelets serotonin content was not signiﬁcantly
different between Child-pugh grade C and grade A/B and con-
cluded that plasma serotonin is a better marker of liver insuf-
ﬁciency than platelet serotonin content.
In this work, platelets serotonin was not measured and
platelets count was low in both groups but was signiﬁcantly
lower in group II than group I (p= 0.036*) (Table 3).
Marasini et al.65 described a signiﬁcant reduction of seroto-
nin in platelets of patients with liver cirrhosis, although the le-
vel of plasma serotonin was within the normal range In the
study of Beaudry et al.,66 the whole blood serotonin level
was signiﬁcantly lower in patients with cirrhosis than in age
matched controls, and no correlation was found between these
levels and the severity of cirrhosis but the unconjugated plas-
ma serotonin level, an indication of the active form of seroto-
nin, was signiﬁcantly higher in patients with cirrhosis than in
the controls.
Platelets are able to attract serotonin from the gut and lung.
Serotonin is present in high concentration in platelets, where it
accumulates from the plasma via the active transport system
SERT. Thus, serotonin participates in the aggregation of
platelets and the coagulation of blood.67 Operating as buffers,
platelets maintain low levels of free circulating serotonin. As
the carrier and reservoir, platelets store serotonin in dense elec-
tron granules.68
Lesurtel et al.69 identiﬁed platelets as the major source of
serotonin that drives liver regeneration in partial hepatectomy
of (PHx) mice. They found that liver regeneration in thrombo-
cytopenic mice following PHx was restored by supplementing
the mice with platelet-rich plasma containing near weight lev-
els of serotonin.
Lafﬁ et al.32 gave evidence for signiﬁcant reduction of sub-
stances that are deposited in thick and in alpha granules in pa-
tients with liver cirrhosis, a condition deﬁned as ‘‘platelet
exhaustion’’.
Culaﬁc et al.38 concluded that plasma serotonin was signif-
icantly higher in patients with cirrhosis than in the controls
and represents the degree of liver insufﬁciency (Table 8). It
was noticed that liver regeneration and repair were signiﬁ-
cantly impaired in platelet-depleted animals. Mice lacking
peripheral serotonin showed a failure of hepatocyte prolifera-
tion after ischaemia, but otherwise displays normal
tissue remodelling. The results suggest that platelets may not
cause postischaemic liver injury, but mediate tissue repair
through modulation of inﬂammation and the release of
serotonin.31nd serotonin in liver Cirrhosis group.
nsitivity Speciﬁcity PPV NpV Accuracy
.11 100.0 100.0 31.25 60.0
.67 100.0 100.0 62.50 89.09
Table 9 Agreement (sensitivity, speciﬁcity and accuracy) for AFP and serotonin in liver Cirrhosis and the HCC group.
Control Liver Cirrhosis + HCC Sensitivity Speciﬁcity PPV NPV Accuracy
AFP >10 10 2 93.33 100.0 100.0 83.33 95.0
610 0 28
Serotonin >75 10 0 100.0 100.0 100.0 100.0 100.0
376 H.A. Abd El Moety et al.APRI score was signiﬁcantly higher in group II than group
I (p< 0.001*) also a signiﬁcant negative correlation was found
between serotonin level and APRI score in group II patients
who had both higher serotonin and APRI score (r= 0.363,
p= 0.049*). Similar results obtained by Loftis et al58 who
demonstrated an association between higher serotonin level
and lower APRI score suggesting that higher serotonin levels
might be a surrogate marker of less advanced liver disease.
The involvement of serotonin in the induction of hepato-
cyte DNA synthesis was ﬁrst investigated in primary cultures
of adult rat hepatocytes by Balasubramanian et al.,70 who
showed that 5-HT could signiﬁcantly induce hepatocyte prolif-
eration in the presence of insulin and EGF (epidermal growth
factor) (Table 9).
Among serotonin receptors the 5-HT2B receptor has been
strongly associated with increased hepatic stellate cells (HSCs)
proliferation and liver ﬁbrosis. HSCs have been reported to se-
crete numerous factors that inﬂuence hepatocyte proliferation.
The role of serotonin as a mitogen for HSCs during liver
regeneration remains hugely unknown.30,71
Serotonin signalling seems to play a pivotal role in deter-
mining the balance between regeneration and ﬁbrogenesis in
chronic liver disease and it has been reported that the activa-
tion of 5-HT2B receptor on ﬁbrogenic HSCs suppresses hepa-
tocyte proliferation through augmented production of
TGFb1.72 At the severe end of the spectrum, 5-HT has been
involved in the pathogenesis of human HCC through increased
5-HT2B expression, which seems to facilitate the survival of
carcinoma cells and to inhibit autophagy.48 It has also been re-
ported to exert a proliferative effect on cholangiocytes and to
promote cholangiocarcinoma growth.73 There are also some
interesting reports suggesting that serotonin can potentially
contribute to liver tissue hypoperfusion following hepatic
ischaemia and reperfusion in canines raising new dilemmas
about its effects on hepatic regeneration.19,74
Serotonin can be potentially associated with either beneﬁ-
cial or detrimental effects on liver regeneration and these ac-
tions are mediated through many different receptor subtypes
located either centrally or peripherally.71
A signiﬁcant positive correlation was found between serum
serotonin and AFP in group I and group II (r= 0.298,
p= 0.047*, r= 0.468 and 0.009*, respectively) (Table 6), so
higher AFP is associated with higher serotonin This signiﬁes
the association between AFP and serotonin and so the impor-
tance of serum serotonin as a marker of HCC and together
with the results of ROC curve in both groups can consider
serotonin as a good marker for the diagnosis of HCC).
6. Conclusion
plasma serotonin levels are signiﬁcantly higher in patients with
cirrhosis and HCC than in cirrhosis in the control groups andis involved in the tumourigenesis of hepatocellular carcinoma
the third cause of cancer-related death worldwide.References
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